Intranasal Insulin in Frontotemporal Dementia (FTD)
Status:
Suspended
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This project will study intranasal (IN) insulin in Frontotemporal dementia (FTD) in 12
patients. Study Investigators aim to evaluate the feasibility of the EXAMINER cognitive
battery as a cognitive outcome measure in FTD, the ability of the HealthPartners Center for
Memory and Aging's ability to sufficiently recruit subjects with FTD, and the safety of IN
regular insulin administered 20 IU twice per day in two specific variants of FTD (behavioral
variant frontotemporal dementia (bv-FTD), semantic dementia (SD)) over a 4 week period.